Results of a clinical trial underway in Spain show a new intravenous drug may help combat a strain of hospital-acquired pneumonia that often proves deadly for patients.
In an April 24 announcement, Pfizer Inc. said tests show its Zavicefta is effective against Gram-negative bacteria, which are becoming increasingly resistant to antibiotic treatments.
The REPROVE test studied the response of 879 patients from 23 countries, the release said. In the Phase 3 trial, which is typically the final step before drugs receive approval and can be prescribed, results showed Zavicefta cure rates were comparable to standard-of-care drug Meropenem with similar tolerability.
Dr. Antoni Torres, a professor at the University of Barcelona's Respiratory Institute who is a lead researcher in the clinical trial, said methods to treat such illnesses have become scarce.
“These study results expand physician options in effectively treating patients with hospital-acquired pneumonia,” Torres said in the release.